Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents
Susan Cornell
Journal of Clinical Pharmacy and Therapeutics (2020) Vol. 45, Iss. S1, pp. 17-27
Open Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Trial of Lixisenatide in Early Parkinson’s Disease
Wassilios G. Meissner, Philippe Rémy, Caroline Giordana, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1176-1185
Closed Access | Times Cited: 130
Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center
Karen Muschler, Rachael Muschalek, Christopher Hoyte
Clinical Toxicology (2025), pp. 1-4
Closed Access | Times Cited: 3
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
Vanita R. Aroda, Lawrence Blonde, Richard E. Pratley
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 23, Iss. 5, pp. 979-994
Open Access | Times Cited: 49
Efficacy of Fasting in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review
Daniel Herz, Sandra Haupt, Rebecca T. Zimmer, et al.
Nutrients (2023) Vol. 15, Iss. 16, pp. 3525-3525
Open Access | Times Cited: 25
Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide
Soraia Pinto, Mahya Hosseini, Stephen T. Buckley, et al.
Journal of Controlled Release (2024) Vol. 366, pp. 621-636
Open Access | Times Cited: 14
Anti‐obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta‐analysis to inform the 2023 international evidence‐based guideline
Alyse S. Goldberg, Sandro Graca, Jing Liu, et al.
Obesity Reviews (2024) Vol. 25, Iss. 5
Open Access | Times Cited: 14
Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials
Gustavo de Oliveira Almeida, Thiago Nienkötter, Caroline Cristine Almeida Balieiro, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 4, pp. 509-521
Closed Access | Times Cited: 11
Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease
Manuel Soto‐Catalán, Lucas Opazo-Ríos, Hernán Quiceno, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2961-2961
Open Access | Times Cited: 9
Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes
Receptors (2025) Vol. 4, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
Comparison of the efficacy and safety of GLP‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis
Xuedong An, WenJie Sun, Zhige Wen, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access | Times Cited: 1
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis
Yuntao Nie, Yiran Zhang, Baoyin Liu, et al.
Obesity Surgery (2025)
Closed Access | Times Cited: 1
Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Geke Aline Boer, Jens J. Holst
Biology (2020) Vol. 9, Iss. 12, pp. 473-473
Open Access | Times Cited: 66
A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
Li Chen, Jiayi Zhang, Yu Sun, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 18
Pharmacotherapy before and after bariatric surgery
Khaled Alabduljabbar, Carel W. le Roux
Metabolism (2023) Vol. 148, pp. 155692-155692
Closed Access | Times Cited: 18
Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017–2022
Christopher E. Gaw, Hannah L. Hays, Cydney A. Kemp, et al.
Journal of Medical Toxicology (2024) Vol. 20, Iss. 2, pp. 193-204
Open Access | Times Cited: 8
Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes
Moeber Mahzari, Omar Buraykan Alluhayyan, Mahdi Almutairi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100343-100343
Open Access | Times Cited: 7
Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism—A Narrative Review
Zsolt Szekeres, András Nagy, K. Jahner, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8214-8214
Open Access | Times Cited: 7
Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
Bruno Vergès, Victor Aboyans, Denis Angoulvant, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 27
Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus
Chih‐Chun Chuang, Kai Wang, Chao‐Kai Chang, et al.
International Journal of Medical Sciences (2024) Vol. 21, Iss. 3, pp. 540-546
Open Access | Times Cited: 5
G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
Mohan Patil, Ilaria Casari, Leon N. Warne, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116245-116245
Open Access | Times Cited: 5
Unlocking the Potential: Semaglutide’s Impact on Alzheimer’s and Parkinson’s Disease in Animal Models
Andreea-Daniela Meca, Ianis Kevyn Stefan Boboc, Liliana Mititelu-Tarțău, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 6, pp. 5929-5949
Open Access | Times Cited: 5
Glucagon-like Peptide-1 Receptor Agonists and Capsule Endoscopy in Patients with Diabetes: A Matched Cohort Study
Tarek Odah, Asrita Vattikonda, Mark E. Stark, et al.
Gastrointestinal Endoscopy (2024)
Closed Access | Times Cited: 5
Advances in venom peptide drug discovery: where are we at and where are we heading?
Taylor B. Smallwood, Richard J. Clark
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 10, pp. 1163-1173
Closed Access | Times Cited: 32
Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future
James P. Psaltis, Jessica A. Marathe, Mau T. Nguyen, et al.
Medicinal Research Reviews (2024) Vol. 45, Iss. 1, pp. 29-65
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top